Editor’s Note: As of May 7, 2025 Minaris Regenerative Medicine became Minaris Advanced Therapies. The announcement below reflects the name of our organization at the time of publication.
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. September 24, 2024.
Minaris Regenerative Medicine (“Minaris”), a leading cell therapy contract development and manufacturing organization, is pleased to announce that its parent company, Resonac Corporation (“Resonac”), has entered into a definitive agreement to sell Minaris to a fund managed by Altaris, LLC (collectively with its managed funds, “Altaris”). Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Subject to customary closing conditions, Resonac has agreed to transfer all issued shares of the three Minaris subsidiaries (Minaris Regenerative Medicine, LLC in the United States, Minaris Regenerative Medicine Co., Ltd. in Japan, and Minaris Regenerative Medicine GmbH in Germany) to Altaris.
“The agreement to transfer shares of Minaris to Altaris, a firm with a track record of building companies that deliver value to the healthcare system, should prove to be transformative for Minaris,” said Dr. Hiroto Bando, CEO of Minaris. “We look forward to partnering with Altaris as we continue to grow our business globally.”
During this interim period, Minaris’ daily business operations, and commitment to its clients, remains the same.
Resonac has issued a press release about this transaction located here (https://www.resonac.com/news/2024/09/24/3285.html)
About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com